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Occam’s dull razor 
MDM2 and P/CAF keep 
Chk2 in check the hard 
way
As is the case for most stress response factors, 
the activity of Chk2 kinase, a central effector of 
the DNA damage response, is homeostatically 
regulated by a fine balance of positive and nega-
tive regulation. Prives and colleagues investigate 
the negative regulation of Chk2 by ubiquitin/
proteasome degradation in the February 1, 2009 
issue of Cell Cycle,1 and in so doing, expose 
a significant gap in our somewhat dogmatic 
knowledge of MDM2 biology and function. Kass 
et al. show that both MDM2, a well-studied 
E3 that targets p53, and the recently identified 
E3, P/CAF2 (better known for its HAT function 
and participation in transcription regulation), 
target Chk2 for ubiquitination and degrada-
tion. Targeting of Chk2 by MDM2 was blocked 
by DNA damage stimulated phosphorylation of 
Chk2 S456, allowing for stress induced stabiliza-
tion of Chk2 during DNA damage responses. 
Unexpectedly, the ability of MDM2 to ubiquitinate 
Chk2 did not require its RING E3 domain, which 
is required for ubiquitination of all of its other 
known targets—most notably, p53. Given that 
P/CAF binds and ubiquitinates MDM2, the authors 
also looked for an impact of P/CAF on Chk2, and 
found that it independently ubiquitinated and 
destabilized Chk2. MDM2 and P/CAF together 
synergistically ubiquitinated Chk2, and all three 
molecules could be found in one complex. As 
seen with MDM2, mutation of the putative P/CAF 
E3 domain had no effect on its Chk2 destabilizing 
activity. The authors propose that P/CAF and 
MDM2 may act within a larger multi-subunit E3 
(a la SCF or APC) to target Chk2, and serve 
mainly as recognition factors/scaffolds rather than 
actual E3 enzymes. In support of this idea, MDM2 
interacted more strongly with Chk2-S456A, a 
mutant which is preferentially hyperubiquitinated 
in the presence of MDM2.
Presuming the effects of P/CAF and MDM2 on 
Chk2 ubiquitination are direct—this work leaves 
the obvious mystery of the identity of the Chk2 
E3. What known MDM2-P/CAF binding part-
ners might be viable candidates? Most obvious 
is MDM-X, the heterodimerization partner of 
MDM2.3 MDM-X, though structurally similar to 
MDM2, with a conserved C-terminal RING E3 
domain, does not target p53 for degradation by 
itself. It can participate with MDM2 in targeting 
p53 when heterodimerized (or perhaps in larger 
oligomeric complexes) with MDM2. Thus, if the 
MDM2 E3 defective mutant and the E3-defective 
P/CAF mutant can both interact with MDM-X, 
perhaps its RING contributes the missing E3. 
Another viable candidate would be CUL4 and 
its associated SCF complex, as two publications 
have identified CUL4 as a direct binding partner 
of MDM2, and also a participant with MDM2 in 
p53 ubiquitination.4,5
Lastly, p300 and/or CBP may provide the 
missing E3 activity. p300 interacts with both 
MDM2 and P/CAF through separate domains 
(C/H1-TAZ1 and C/H3-TAZ2, respectively), while 
p300 and P/CAF both interact with MDM2 
through its central domain.2,6,7 Thus, there is a 
distinct possibility given all the possible contact 
surfaces, that p300 (and/or CBP), P/CAF and 
MDM2 participate in a tripartite complex that 
could then interact with Chk2. p300/CBP are 
better known as HATs (as is the distantly related 
P/CAF) that globally regulate histone acetylation, 
but also act as non-histone acetylases that regulate 
dozens (at least) of transcription factors, most 
notably, p53. The ubiquitin ligase activity of p300 
was recently described as specifically targeting 
p53 for polyubiquitination, but only when p53 
had been oligoubiquitinated by MDM2 first.8 CBP 
shares a similar “E4” activity for p53.9 This activity 
is centered within the N-terminal 595 amino acids 
of p300 where a substrate independent generic 
E3 activity is also located. Initially perplexing was 
the lack of a canonical E3 domain in p300 (RING, 
Hect, U-box, etc.), but since 2003 there has been 
a growing list of such non-canonical E3’s, which 
includes A20,10 P/CAF and Rabex-5.11 Though 
no evolutionarily conserved domains are shared 
by these proteins, at least p300 and A20 share 
non-RING (and non-homologous) Zn2+-binding 
domains, which are required for E3 activity, or 
are at least present within the putative E3 domain. 
P/CAF has a potential Zn2+ binding sequence 
within its E3 domain, and this sequence aligns with 
a portion of p300 TAZ1 sequence.12 Given that 
p300 and P/CAF do share evolutionary origins, 
their E3 domains may very well share struc-
tural similarity, perhaps centering on the known 
(for p300) and putative (for P/CAF) Zn2+-binding 
domains of each protein.
Setting aside the details of exactly how MDM2 
and P/CAF accomplish the ubiquitination of Chk2 
without their own E3 domains, one wonders—
why this way? Given evolutionary pressures, 
the regulation of Chk2 may have evolved in this 
manner due to the need for Chk2 ubiquitination 
in contexts where the MDM2 RING or P/CAF 
E3 domains are not available. Two possibilities 
arise. Perhaps the Chk2 regulatory function was 
encoded in a more evolutionarily ancient form 
of MDM2 or P/CAF, prior to E3 activities being 
joined to the molecules. More likely, especially for 
MDM2, there are prevalent forms of the molecule 
that lack the RING domain, yet should still bind to 
Chk2 and P/CAF. A substantial fraction of MDM2 
protein exists in a caspase-cleaved form, where 
cleavage after residue 361 by distinct caspases 
in resting13 and apoptotic14 cells, leaves intact a 
C-terminally truncated RING-less form that main-
tains an intact central domain, and presumably, 
p300 and P/CAF binding activities. As the exact 
functional relevance of caspase-cleaved MDM2 
has remained mysterious, perhaps examination 
of its effects on Chk2 in resting, DNA damaged 
and apoptotic cells would be worthwhile, and 
also shed light on why nature seems to have 
chosen an arcane mechanism more reminiscent 
of Rube Goldberg than Occam, when it comes to 
MDM2-P/CAF regulation of Chk2.
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Strong inducible knock-
down of Cdc20 does not 
cause mitotic arrest in 
human somatic cells
Implications for cancer 
therapy?
Eukaryotes have evolved to initiate the sepa-
ration of their sister chromatids in a highly 
synchronous manner at the onset of mitotic 
anaphase. This promotes the fidelity of chromo-
some segregation. Anaphase is triggered as 
a result of the degradation of proteins that 
become ubiquitinated by the Anaphase Promoting 
Complex/Cyclosome (APC/C). The APC/C is a 
multi-subunit complex1 which requires a specificity 
factor, Cdc20, to facilitate the ubiquitination of 
the known anaphase targets, securin and cyclin 
B.2 The spindle assembly checkpoint (SAC) is a 
mechanism that inhibits Cdc20 until anaphase 
initiation is appropriate. This mode of anaphase 
regulation has become widely accepted as the 
mechanism that controls chromosome segregation 
in eukaryotes. However, recent studies indicate 
that anaphase can occur in the absence of Cdc20 
and also that the SAC can restrain anaphase 
independently of inhibiting APC/C activity. These 
News & Views
© 
20
09
 LA
ND
ES
 BI
OS
CIE
NC
E. 
DO
 NO
T D
IST
RIB
UT
E.
516 Cell Cycle 2009; Vol. 8 Issue 4
News & Views
hormone, follicle cells secrete a steroid, e.g., 
progesterone, that acts on a membrane receptor 
in the oocyte to induce maturation.
In a paper published in this issue of Cell Cycle, 
Pirino and colleagues provide compelling evidence 
that PKA-mediated phosphorylation of CDC25B 
is essential to maintain meiotic arrest in mouse 
oocytes.3 Mouse oocytes express three forms of 
CDC25, namely, CDC25A, -B and -C. Cdc25c 
null mice are fully fertile, excluding a role for this 
isoform in maintaining meiotic arrest. Cdc25a null 
mice are embryonic lethal, but results of recent 
experiments suggest that although CDC25A is 
involved in maturation, it is not the primary family 
member responsible for maintenance of meiotic 
arrest.4 In contrast, Cdc25b is clearly implicated 
in maintaining meiotic arrest because Cdc25b null 
female mice are infertile and oocytes obtained 
from such mice do not initiate maturation, i.e., 
breakdown of the nuclear membrane.5 Moreover, 
expressing an active form of CDC25B in Cdc25b 
null oocytes results in resumption of meiosis and 
activation of CDC2A, whereas expressing a cata-
lytically inactive form of CDC25B in these oocytes 
fails to initiate meiotic maturation. 
Pirino and colleagues report that CDC25B 
is directly phosphorylated by PKA on S321, 
consistent with results of immunoprecipitation 
experiments using a FLAG-HA-mCherry-CDC25B 
that document an interaction with PKA. In addition, 
expressing a mutated form that cannot be phos-
phorylated (S321A) results in oocytes undergoing 
maturation in the presence of a phosphodisterase 
inhibitor. In Xenopus, CDC25C appears to be the 
target of PKA, and phosphorylation of CDC25C 
generates a binding site for a 14-3-3 protein 
that sequesters CDC25C within the cytoplasm, 
thereby preventing translocation to the nucleus 
where it functions. A similar situation appears in 
mouse in which CDC25B phosphorylation gener-
ates a 14-3-3 binding site that results in CDC25B 
localizing to the cytoplasm. For example, FLAG-
HA-mCherry-CDC25BS321A quickly localizes to 
the nucleus whereas FLAG-HA-mCherry-CDC25B 
remains in the cytoplasm. 
With CDC25B serving as a target for PKA in 
which CDC25B function is inhibited by its associa-
tion with 14-3-3 and PKA mediating an activating 
phosphorylation of WEE1B, what emerges is a 
simple model for the role of PKA in maintenance 
of meiotic arrest and resumption of meiosis. In the 
presence of elevated levels of cAMP, the ability of 
PKA both to inhibit CDC25B and activate WEE1B 
maximally suppresses CDC2A-CCNB activity and 
thereby maintains meiotic arrest. The maturation-
associated decrease in oocyte cAMP triggers 
resumption of meiosis by decreasing PKA activity 
with the concomitant activation of CDC25B and 
inhibition of WEE1B, the outcome being activa-
tion of CDC2A. After about 35 years since first 
ascribing a role for cAMP in oocyte maturation, 
the circle is finally closed.6 
undergo mitosis due to the APC/C-independent 
pathway. Anaphase is abnormal in these cells 
providing the opportunity for chromosome loss 
which could be an advantage to the cancer cells. 
However, the APC-independent mechanism that 
promotes anaphase might be crucial for tumor 
survival. The identification of this pathway could 
reveal novel therapeutic targets.
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PKA and CDC25B
At last connected
Mouse oocytes grow while arrested in the first 
meiotic prophase. Following completion of growth 
a surge in luteinizing hormone initiates resumption 
of meiosis and ovulation. It is well established 
that activation of the cyclin-dependent protein 
kinase CDC2A-CCNB (M-phase promoting factor) 
triggers resumption of meiosis. There is also 
a large body of evidence that PKA is essen-
tial to maintain meiotic arrest. For example, a 
decrease in cAMP concentration occurs during the 
time when oocytes become committed to resume 
meiosis; cyclic nucleotide phosphodiesterase inhib-
itors and membrane-permeable cAMP analogs 
prevent maturation; and injecting oocytes with 
the catalytic subunit of PKA inhibits maturation, 
whereas injecting oocytes with the PKA inhibitor 
PKI overcomes inhibition of maturation in response 
to cyclic nucleotide phosphodiesterase inhibitors 
and membrane-permeable cAMP analogs. What 
is unresolved to date is how PKA prevents acti-
vation of CDC2A-CCNB and hence initiation of 
maturation.
The activity of CDC2A-CCNB is regulated 
by phosphorylation (as well as by proteolysis 
of cyclin). Phosphorylation of T14 and Y15 in 
CDC2A is catalyzed by members of the WEE1 
family of protein kinases and inhibits the kinase 
activity of CDC2A. Reciprocally, dephosphoryla-
tion of these residues by a dual specificity protein 
phosphatase CDC25 activates CDC2A. 
Much evidence indicates a role for PKA in 
activating WEE1.1,2 Mouse oocytes contain an 
oocyte-specific form of WEE1, WEE1B. RNAi-
mediated degradation of Wee1b mRNA results 
in oocytes maturing in the presence of high levels 
of cAMP and hence PKA activity. Furthermore, 
PKA-mediated phosphorylation of S15 on WEE1B 
increases its kinase activity and expressing in 
Xenopus oocytes a putative constitutively active 
form of WEE1B in which S15 is mutated to an 
aspartate reside inhibits progesterone-induced 
maturation; in Xenopus, in response to luteinizing 
studies suggest that redundant mechanisms control 
anaphase progression.
In the article published in this issue of Cell 
Cycle by Baumgarten et al., the authors ask 
what are the consequences of Cdc20 depletion 
from human cultured cells. This question has 
been addressed in other published articles but 
the published data are somewhat contradictory, 
perhaps due to different depletion approaches 
and/or efficiencies. In this study the authors 
used probably the best method to achieve deple-
tion (lentiviral vector-mediated RNA interference) 
and the efficiency seems exceptionally strong. 
Moreover, the authors derived clonal cell lines 
in which Cdc20 depletion is inducible. The find-
ings of this work are quite striking as the authors 
provide evidence that Cdc20 depletion does 
not arrest the cell cycle or greatly stabilize the 
substrates of the APC/C, cyclin B and securin.3 
Their conclusion is that a redundant mechanism 
allows mitotic progression in the absence of 
APC/C-Cdc20 activity. The authors go on to show 
that securin and cyclin B become stabilized in the 
absence of Cdc20 only when the SAC is activated 
by nocodazole treatment. In other words, a part 
of the SAC pathway must be able to act inde-
pendently of Cdc20 inhibition and this activity is 
capable of blocking anaphase onset.
This work adds to a growing literature which 
has revealed inconsistencies in the current 
model of anaphase control. Depletion of Apc2 
(an essential catalytic subunit of the APC/C) from 
human somatic cells4 delays but does not prevent 
sister chromatid separation in anaphase but these 
cells do arrest in telophase. This result indicates 
that the APC/C is not the sole pathway capable 
of promoting anaphase progression. Similar to 
the above study, in these experiments anaphase 
was initiated in the absence of APC activity but 
upon the addition of nocodazole, anaphase 
was blocked. Thus, an alternate SAC pathway 
can control anaphase onset independently of 
the APC/C. It is becoming clear that the APC/C 
promotes mitotic progression in collaboration with 
underlying redundant safety features that together 
provide fidelity.
Yeast cells that lack APC/C catalytic subunits 
and also lack Cdc20, securin and Clb5 
(a B-type cyclin) are able to perform anaphase 
with sufficient fidelity to remain viable. In these 
cells, there remains a SAC response to nocoda-
zole which results in metaphase arrest.5 Deletion 
of the MAD2 SAC gene does not overcome the 
checkpoint arrest. These yeast genetic experi-
ments are consistent with the results presented 
by Baumgarten et al. In both the yeast and 
human cells lacking Cdc20, mitotic arrest was 
induced upon activation of the SAC. The simplest 
interpretation of these data is that mitosis can be 
completed in the absence of Cdc20 and that the 
SAC does more that just inhibit Cdc20.
These studies may have implications for cancer 
therapy. An important discovery was that some 
aggressive tumors have reduced APC/C activity 
due to constitutive high levels of the Mad2 SAC 
protein.6 It is plausible that these cells are able to 
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cells harboring an ime2 deletion and inducing the 
cells to initiate meiotic differentiation. While none 
of the Cdks tested could fully rescue meiosis and 
gamete formation, data are presented suggesting 
that Cdk2 may have the ability to partially 
suppress the defects in DNA replication and the 
expression of a subset of meiosis-specific genes. 
Although it may be an over statement to call Cdk2 
a true functional homolog of Ime2, it does appear 
to perform a subset of the same functions. Given 
the array of meiosis-specific tasks performed by 
Ime2 it is perhaps not surprising that Cdk2 could 
not provide a full replacement of its functions. The 
consensus sites for phosphorylation by Cdk2 or 
the yeast Cdc28 (S/T*-P-x-K/R) and Ime2 (R-P-x-
S/T*-A/G) are different however many of the 
same proteins phosphorylated by yeast Cdc28 
can also be phosphorylated by Ime2. In some 
cases, the same sites are phosphorylated but in 
others different sites are targeted but the same 
end is achieved. Only a fraction of all Ime2 
substrates have been identified and it is likely 
that at least a subset will be targeted by Ime2 but 
not Cdk activity. The difference in consensus sites 
likely ensures that some protein substrates that are 
specific for Cdk and some for Ime2. 
Interestingly mammalian cells express a testis 
specific protein kinase Mak1 (male germ-line asso-
ciated kinase) and a close homolog MRK1 (Mak1 
Related Kinase) that are similar to Ime2 and 
display a similar phosphorylation site consensus 
(R-P-x-S/T-P).4 At least in mice Mak1 is not 
essential for meiosis.5 Perhaps the overlapping 
consensus phosphorylation sites between Mak1 
and Cdk2 allow Cdk2 to perform all of the neces-
sary meiotic functions in the absence of Mak1 but 
further investigation of the roles of both enzymes 
in meiosis are needed before such a conclusion 
can be drawn.
A particularly interesting question raised by 
this work is: what yeast cyclins are binding to and 
activating Cdk2 in these experiments? Cyclins 
typically provide substrate specificity to the Cdk 
and in yeast Clb5 and Clb6 bind yeast Cdk1 
to promote meiotic DNA replication, however, 
they cannot replace Ime2. In mammalian meiosis 
Cdk2 pairs with cyclin A1 to perform its functions. 
Perhaps the heterologous pairing of human Cdk1 
and yeast cyclins provides Cdk2 with a substrate 
specificity that allows it to perform Ime2 functions. 
Or perhaps Cdk2 is activated by a yeast non-
cyclin protein providing it with a new substrate 
specificity. Whichever is the case, the authors 
suggest that Cdk2 can fulfill some of the same 
functions as Ime2, although the ability of Cdk2 
to perform those functions is limited. A compre-
hensive understanding of the role Cdk2 plays 
in meiosis will require extensive investigations 
in an animal model. However, since the basic 
meiotic processes are similar between yeast and 
mammals, the genetically tractable yeast model 
may be a tool to reveal the essential functions 
and substrates of Cdk2 in mammalian gameto-
genesis. 
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Crossing borders in search 
of functions
The role of Cdk2 in 
meiosis
The eukaryotic cell cycle is tightly orchestrated 
to achieve optimal proliferation as dictated by 
external conditions or the surrounding cellular 
milieu. This finely tuned process can also be 
modified when necessary to allow cellular differ-
entiation and the achievement of developmental 
goals. Meiosis and gamete formation is one 
example of a differentiation process in which the 
cell cycle is modified to produce cells that can 
perform a specific function. The molecular details 
of mammalian gametogenesis have been difficult 
to decipher due to our inability to effectively 
recapitulate the process in vitro. In contrast, the 
budding yeast Saccharomyces cerevisiae has 
proven to be an exceptional model for gameto-
genesis in that it is genetically tractable and can 
be induced to synchronously initiate and proceed 
through the process. 
Cyclin dependent kinases (Cdks) provide the 
major impetus for progression through cell cycle 
transitions during both mitotic proliferation and 
meiotic differentiation. Mammalian cells express 
several Cdks that participate in cell cycle regula-
tion: Cdk1, Cdk2, Cdk4 and Cdk6. Although 
deletion of any of the Cdks is deleterious, it has 
come as a surprise that only Cdk1 is essential.1 
Cdk2 appears to have a critical role in gamete 
formation. Cdk2-/- mice are viable but display 
infertility with germ-line cells arresting prior to the 
first meiotic division.2
In this issue of Cell Cycle, Szwarcwort-Cohen 
et al.,3 have postulated that Cdk2 is a functional 
homolog of the budding yeast meiosis-specific 
protein kinase Ime2. The yeast Ime2 displays 
sequence similarity to Cdks but unlike Cdks does 
not require a cyclin partner for activity. Ime2 
performs multiple functions in meiosis ranging from 
the regulation of meiosis-specific gene expression 
to initiating DNA replication and meiotic chromo-
some divisions. Although Ime2 is Cdk-like and 
performs many essential functions in meiosis it 
cannot replace the yeast Cdk1 homolog Cdc28 
which is required to promote DNA replication 
and the meiotic chromosome divisions both during 
meiosis and during mitotic growth. 
Szwarcwort-Cohen et al. tested their hypoth-
esis by expressing Cdk1, Cdk2 or Cdk4 in yeast 
